tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Nuvilex, Inc. COO Discusses Upcoming Phase III Pancreatic Cancer Trials

Nuvilex, Inc. COO Discusses Upcoming Phase III Pancreatic Cancer Trials

Dr. Gerald Crabtree Addresses Study Sites, Seeking Fast Track & Orphan Drug Status and More

Written by ι Stock Market Media Group Staff — May 13, 2013

Nuvilex, Inc. (OTCQB: NVLX) COO Dr. Gerald Crabtree is no stranger to late stage clinical trials or dealing with blockbuster therapies for cancer patients.  It’s likely that is exactly why he’s the COO at the small Silver Spring, Maryland, biotech.  The road that Nuvilex is currently on – preparing for a large scale Phase III clinical trial ...

Read More →
0

Plandai Biotechnology, Inc. Molecularly Changing the Botanical Extract Industry

Plandai Biotechnology, Inc. Molecularly Changing the Botanical Extract Industry

Written by ι Stock Market Media Group Staff — May 8, 2013

That loud noise coming from the botanical extract industry is Plandaí Biotechnology, Inc. (OTCQB: PLPL) landing on the scene with three highly bioavailable products that will likely change the way we look at botanical extracts for years to come.  This Seattle based biotechnology firm uses a proprietary process that is dramatically improving the bioavailability of their compounds through molecular changes to the live botanicals themselves.  So much so, that when the ...

Read More →
0

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Written by ι Stock Market Media Group Staff — May 7, 2013

Nuvilex, Inc. (OTCQB: NVLX) should be convincing investors by now that its technology could truly change the face of healthcare.  Many know of the company’s “Cell-in-a-Box” technology for its performance in clinical trials for advanced, inoperable pancreatic cancer, and its performance in pre-clinical studies for diabetes where it essentially created a type of “artificial pancreas.”  But, the company isn’t stopping there when it comes to showing the technology’s flexibility.

“Cell-in-a-Box” or living ...

Read More →
0

Nuvilex, Inc. Pancreatic Cancer Trials Could Make “Cell-in-a-Box” Gold Standard

Nuvilex, Inc. Pancreatic Cancer Trials Could Make “Cell-in-a-Box” Gold Standard

Written by ι Stock Market Media Group Staff — April 29. 2013

While many biotech and pharmaceutical companies are designing one drug after another to address specific problems, Nuvilex, Inc. (OTCQB: NVLX) is using its own living cell encapsulation as a “one size fits all” type solution.  The company is off to a great start at getting its “Cell-in-a-Box” technology on the map with its work in late stage, inoperable pancreatic cancer. 

Nuvilex is headquartered in Silver Spring, Maryland, and while it is a ...

Read More →
0

Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It

Potential Future Sales of Nuvilex, Inc. Cancer Treatments Make Investment in Cell-in-a-Box Worth It

Written by ι Stock Market Media Staff — March 26, 2013

Nuvilex, Inc. (OTCQB: NVLX) is a small biotechnology company out of Silver Spring, Maryland, but its future might be anything but small.  As the company diligently prepares for its Phase III pancreatic cancer trials, the almost $30-million the company has invested in its unique and proprietary living cell encapsulation or “Cell-in-a-Box” technology could be money well spent given the return in annual sales that cancer drugs bring ...

Read More →
0

Nuvilex, Inc. Price Valuation Justifies Investor Confidence in Biotech

Nuvilex, Inc. Price Valuation Justifies Investor Confidence in Biotech

Written by ι Stock Market Media Group Staff — April 25, 2013

Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology firm quietly going about its business in Silver Spring, Maryland.  The company is currently priced below $0.10/share, and according to a recent valuation report, at this price, it is highly undervalued given the work going on at Nuvilex.

Goldman Small Cap Research released a valuation of Nuvilex based upon its work with pancreatic cancer and its future potential in the medical marijuana arena.  This ...

Read More →
0
Page 29 of 32 «...10202728293031...»